Novo Nordisk Inks $700 Million Deal with Ventus Therapeutics September 30, 2022 AutoBot News 0 Novo Nordisk will pay up to $700 million for the exclusive rights to develop and commercialize candidates from Ventus Therapeutics NLRP3 inhibitor portfolio.